1 T cell Homeostatic Imbalance in Placentae from Women with HIV in the 2 absence of Vertical Transmission.

3

4 Nadia M. Ikumi¹, Komala Pillay^{2,3}, Tamara Tilburgs^{4,5}, Thokozile R. Malaba⁶,
5 Sonwabile Dzanibe¹ Elizabeth Ann L Enninga⁷, Rana Chakraborty^{7,8,9}, Mohammed
6 Lamorde¹⁰, Landon Myer⁶, Saye Khoo¹¹, Heather B Jaspan¹ and Clive M. Gray^{1,2,12*},
7 for the DOLPHIN-2 Study Group

8

9 ¹Division of Immunology, Institute of Infectious Disease and Molecular Medicine,
10 University of Cape Town, South Africa

11 ²National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South
12 Africa

13 ³Division of Anatomical Pathology, Department of Pathology, University of Cape
14 Town, Cape Town, South Africa

15 ⁴Division of Immunobiology, Center for Inflammation and Tolerance, Cincinnati
16 Children's Hospital, Cincinnati OH 45229, USA

17 ⁵Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati
18 OH 45229, USA

19 ⁶Division of Epidemiology and Biostatistics, School of Public Health and Family
20 Medicine, University of Cape Town, Cape Town, South Africa

21 ⁷Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905

22 ⁸Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine
23 and Science, Minnesota, USA

24 ⁹Department of Immunology, Mayo Clinic, Rochester, MN 55905

25 ¹⁰Infectious Diseases Institute, College of Health Sciences, Makerere University,
26 Kampala, Uganda

27 ¹¹Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK; Royal
28 Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK

29 ¹²Department of Pathology, University of Cape Town, Cape Town, South Africa

30

31 *Corresponding author

32 **Running title:** Altered placental T cell immunity in HIV

33

34 **Word count:** Abstract: 206 words, Lay abstract: 192 words; Main text 3494; 48

35 references; 5 Figures and 2 Tables; supplementary figures <25MB

36 **ABSTRACT**

37 **Background:** Implementation of universal antiretroviral therapy (ART) has
38 significantly lowered vertical transmission rates but has also increased numbers of
39 HIV-exposed uninfected children (HEU), who remain vulnerable to morbidities. Here,
40 we investigated whether T cell alterations in the placenta contribute to altered
41 immune status in HEU.

42 **Methods:** We analyzed T cells from term placentae decidua and villous tissue and
43 paired cord blood from pregnant women with HIV (PWH) who initiated ART late in
44 pregnancy (n=21) with pregnant women not living with HIV (PWNH) (n=9).

45 **Results:** Placentae from PWH showed inverted CD4:CD8 ratios and higher
46 proportions of tissue resident CD8+ T cells in villous tissue relative to control
47 placentae. CD8+ T cells in the fetal capillaries, which were of fetal origin, positively
48 correlated with maternal plasma viraemia prior to ART initiation, implying that
49 imbalanced T cells persisted throughout pregnancy. Additionally, the expanded
50 memory differentiation of CD8+ T cells was confined to the fetal placental
51 compartment and cord blood but was not observed in the maternal decidua.

52 **Conclusions:** T cell homeostatic imbalance in the blood circulation of PWH is
53 reflected in the placenta. The placenta may be a causal link between HIV-induced
54 maternal immune changes during gestation and altered immunity in newborn infants
55 in the absence of vertical transmission.

56

57 **Keywords:** CD4, CD8, T cells, placenta, HIV, HEU, HIV-exposed, placenta
58 pathology, villous tissue

59

60

61 **Lay Summary**

62 The effective prevention of HIV transmission during pregnancy with the rollout of
 63 antiretroviral therapy (ART) has resulted in increased numbers of HIV-exposed
 64 uninfected children (HEU). These children are vulnerable to infections and health
 65 problems and have distorted cellular immune systems at birth. We investigated
 66 whether these immune alterations originate in the placenta, as this fetal organ
 67 maintains life during pregnancy. After collecting placentae at term from pregnant
 68 women living with HIV (PWH), who started ART in the third trimester (n=21) and
 69 from pregnant women not living with HIV (PWNH) (n=9), we isolated T cells from
 70 dissected placental tissue and matching cord blood. Placentae from PWH showed
 71 inverted CD4:CD8 ratios in the placenta and cord blood with higher numbers of
 72 CD8+ T cells in the fetal part of the placenta. These CD8+ T cells mirrored events in
 73 the blood circulation of the mother and the altered balance of T cell immunity in the
 74 PWH was reflected in the placenta. Accordingly, the placenta may be a pivotal link
 75 between HIV-induced maternal immune changes and altered immunity in newborn
 76 infants in the absence of vertical transmission.

77

78 Background

79 In adults, HIV causes severe immune dysregulation, characterized by systemic
80 depletion of CD4+ T cells, increased HIV-1 specific CD8+ T cells, inflammation and a
81 progressive failure of the immune system[1–3]. Initiation of antiretroviral therapy
82 (ART) has been shown to augment HIV-specific CD4+ T cell responses, but
83 normalization of the CD4:CD8 T cell ratio does not occur in a large proportion of
84 people with HIV[4]. In pregnant women living with HIV (PWH), there is evidence that
85 women who initiate ART before pregnancy are more likely to have adverse birth
86 outcomes compared to initiation during pregnancy [5].

87

88 Placentae from PWH exhibit increased signs of inflammation and injury affecting
89 maternal vasculature and circulation[6,7]. Studies also show that using protease
90 inhibitor-based ART during pregnancy associates with placental injury affecting
91 maternal vascularization and impaired decidualization [8,9]. In addition, although the
92 maternal and fetal circulation within the placenta takes place in distinct
93 compartments, there is evidence that maternal HIV and viral load impacts the fetal
94 immune system. HIV-exposed uninfected children (HEU) have been shown to have
95 lower CD4 T cells and CD4:CD8 T cell ratios at birth [10,11] and this appears to be
96 related to maternal viral loads above 1000 RNA copies/ml [12]. HIV-unexposed
97 uninfected children (HUU) have an almost completely naïve T cell repertoire, but at
98 birth HEU can have increased proportions of differentiated immune cells suggestive
99 of antigen experience *in utero*[10,13]. Indeed, a number of factors including impaired
100 thymic output and functioning may underlie the immune alterations in HEU[14,15].
101 Here, we sought to investigate how HIV exposure *in utero* may contribute to altered
102 HEU immunity[16,17].

103

104 To test the hypothesis that maternal HIV infection is associated with disruption of T
 105 cell homeostasis in the placenta and cord blood from HEU newborns, we examined
 106 term placentae from PWH from a randomized trial in pregnant mothers initiating
 107 dolutegravir versus efavirenz-containing therapy in the third trimester (DOLPHIN-2:
 108 NCT03249181)[18], as well as pregnant women not living with HIV (PWNH),
 109 controls. We show that placentae from PWH have inverted CD4:CD8 ratios with
 110 higher CD8+ T cells in villous tissue relative to control placentae contributing to T cell
 111 homeostatic imbalance in the placenta at birth.

112

Methods

Cohort

We included 21 placentae with 9 paired cord blood samples from PWH and HEU and 9 placentae from PWNH with 5 cord blood samples from HUU in this study. The PWH group was nested in the DoIPHIN-2 study recruited from the Gugulethu Community Health Centre, Cape Town[18]. PWNH were enrolled from Khayelitsha Site B Midwife Obstetric Unit, Cape Town. All placentae were from term deliveries (>37 weeks' gestation).

Clinical Data collection

As part of DoIPHIN-2, maternal systemic CD4 T cell counts and plasma viral loads (VL) copies were measured at ART initiation at 28 weeks' gestation (visit 1), 29 weeks (visit 2), 33 weeks (visit 3), 36 weeks (visit 4) and day 14 after delivery (visit 5). The level of HIV-1 RNA detection was 50 copies per ml[18].

Placenta and cord blood processing.

Cells were isolated from each placenta as previously described[19] and illustrated in Supplementary Figure 1. Placentae were collected in RPMI 1640 supplemented with 10% fetal calf serum and penicillin/streptomycin at room temperature and processing was performed within six hours of delivery. Each placenta was dissected to obtain the decidua parietalis, basalis and villous tissue. Enzymatic lymphocyte isolation was performed using Collagenase I and DNase I. The lymphocyte fraction was obtained following Percoll density centrifugation and incubated with violet amine reactive viability dye (VIVID, Thermofisher). The cells were then fixed using BD FACS™

lysing solution and cryopreserved in liquid nitrogen until analysis. Cord blood mononuclear cells were isolated on Ficoll, fixed and cryopreserved until analysis.

Placenta pathology

Whole placentae were fixed in 10% buffered formalin prior to histopathology. Specimens were macroscopically examined and samples from the umbilical cord, placental membranes and placental disk were obtained based on the Amsterdam Placental Workshop Group Consensus Statement[20]. Briefly, four blocks were prepared from each placenta; including a roll of the placental membranes, two cross sections of the umbilical cord; and full-thickness sections of the placental parenchyma and examined in detail as previously described [21].

Flow cytometry

Placental and cord blood cells were labeled with fluorochrome-conjugated monoclonal antibodies: CD3 (Clone UCHT1), CD4 (Clone SK3), CD8 (Clone SK1), CD45RA (Clone H100), CD28 (Clone CD28.2), CD14 (Clone MHCD1417) and CD45 (Clone MHCD4530). Samples were acquired using an LSR II flow cytometer (BD Biosciences). Total CD4+ and CD8+ T cells were expressed as a proportion of CD3+ T cells (Supplementary Figure 2).

Immunohistochemistry

Formalin fixed paraffin embedded (FFPE) placenta tissue blocks were cut into 5 µM sections and stained with CD8 (Clone C8/144B), with tonsillar tissue serving as a control. Briefly, the slides were baked overnight at 56°C and rehydrated in xylene followed by varying concentrations of alcohol and then incubated in 3% hydrogen

peroxide. Heat-mediated antigen retrieval was performed using an EDTA buffer (pH9). The slides were then incubated with 1% Bovine Serum Albumin and stained with anti-CD8. The images were acquired on Zeiss Axioskop 200 upright Fluorescence microscope with an AxioCam high resolution colour (HRC) camera.

Fluorescence in situ hybridization (FISH)

As there were five male babies, we selected those placental samples to identify the origin of the infiltrating lymphocytes by looking for the Y chromosome using XY-FISH. Briefly, the slides were baked at 90°C for 15 minutes, deparaffinized in xylene, dehydrated in 100% ethanol and then placed in 10mM Citric Acid (pH 6.0). The slides were then dehydrated in varying concentrations of ethanol (70%, 85% and 100%). We then applied a working solution of DXZ1/DYZ3 (Abbott Laboratories, Des Plaines, IL, USA) to the target areas, co-denatured with a ThermoBrite (Abbott Laboratories) and hybridized overnight at 37°C. The slides were then counter stained with 4'-6'-diamidino-2-phenylindole (DAPI) (Vector Laboratories). Tissue samples were scanned and the qualitative result was determined based on observed signal patterns by CytoVision (Leica Biosystems, Germany).

Statistics

All flow cytometry data were analyzed using FlowJo version 10 (Treestar). Statistical analyses were performed using Prism version 8 (Graphpad Software), STATA version 12.0 (Stata Corporation) or R[22]. Immunohistochemistry cell counts were performed using Image J Fiji version 2 (WS Rasband, National Institute of Health). Tests of significance were performed using Mann-Whitney *U* and Kruskal-Wallis tests for intergroup comparisons. The associations between cell proportions and

maternal viral load or CD4 T cell counts were assessed using simple linear regression. All bivariate analyses including maternal and infant characteristics, and placental pathology stratified by HIV-exposure or by ART regimen were compared using Chi² or Fisher's exact test and Wilcoxon rank-sum tests.

Study approval

The study protocol, informed consent and all data collection tools were approved by the University of Cape Town, Human Research Ethics Committee (096/2017). Written and signed informed consent was obtained from all participants, including collection of placentae prior to study inclusion.

Results

Participant Characteristics

Maternal and newborn infant characteristics are shown in Table 1. No significant differences in maternal age were noted between PWNH and PWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNH and 39 weeks in the PWH (p=0.03) and there was a lower birthweight trend in HEU (p=0.07). We collected placentae from 21 PWH: 16 (76.2%) receiving efavirenz (EFV+TDF+3TC) and 5 (23.8%) receiving dolutegravir (DTG+TDF+3TC), shown in Supplementary Table 1. Median CD4 count at ART initiation was 358 cells/mm³ (IQR 278–477), with no difference between ART groups (Supplementary Table 2). The median VL at ART initiation was 4.54 log₁₀ RNA copies/ml (IQR 3.85–4.80) in the EFV group versus 3.83 log₁₀ RNA copies/ml (3.49–3.83) in the DTG group, with a combined viraemia of 4.28 log₁₀ RNA copies/ml

(Supplementary Table 2). Both ART groups were on treatment for a median of 84 days IQR (44-105) and women in the DTG arm achieved viral suppression at a faster rate (cut off ≤ 50 copies/ml or $1.69 \log_{10}$ RNA copies/ml) at 4 weeks versus 2 weeks after delivery (Supplementary Table 2 and [18]). For the purposes of this study, we combined the placentae from two ART groups, as there were only 5 collected from the DTG arm.

Placental weight is altered by HIV

Table 2 shows placenta characteristics and pathology stratified by HIV status. PWNH had significantly larger placentae (468g, IQR 426-533) compared to the PWH (394g, IQR 343-469; $p=0.02$), with 38% of placentae in PWH being $<10^{\text{th}}$ percentile weight-for-gestation compared to 0% in PWNH. These differences were also reflected in the fetal-placental (FP) ratios, where all cases with FP ratios $>90^{\text{th}}$ percentile were in the PWH cases ($p=0.02$). Placental histopathology identified 2 cases (9.5%) of chronic deciduitis and 6 cases (28.6%) of MVM, all in the PWH. There were no significant differences in the incidence of meconium exposure and chorioamnionitis between PWH and PWNH, and there was no evidence of villitis of unknown etiology (VUE) in any of the placentae. There were no significant differences in the placental weight, FP ratio and placental pathology between the two ART groups (Supplementary Table 3).

HIV infection during pregnancy alters placental CD4+ and CD8+ T cell proportions

Figure 1A shows significantly lower proportions of CD4+ T cells in decidua parietalis and basalis, but not in the villous tissue, comparing placentae from PWH with PWNH. The proportion of CD8+ T cells was significantly increased (Figure 1A) in all

three placental compartments resulting in significantly lower CD4:CD8 T cell ratios in the three placental tissues from PWH (Figure 1B). Notably, the inverted CD4:CD8 ratio in villous tissue was due to the increased CD8+ T cells in the villous tissue. The inverted CD4:CD8 ratio was partially reflected in cord blood from HEU (Figures 1B). No differences were identified in T cell proportions when stratified by the different ART regimens (Supplementary Figure 3). The proportion of CD4+ and CD8+ T cells in the placenta was not associated with placental weight, gravidity or gestational age at delivery (Supplementary Figures 4, 5 and 6).

Maternal absolute peripheral blood CD4 T cell counts, measured pre-ART at a median of 28 weeks' gestation, positively correlated with the proportion of CD4+ T cells in the decidua and negatively correlated with the proportion of CD8+ T cells in decidua and villous tissue (Figure 1C and D). A similar trend was observed in cord blood. Thus, the inverted placental tissue CD4:CD8+ T cell ratios appeared to reflect the maternal peripheral immune status but was mirrored to a lesser extent in the cord blood of HEU. This correlation was temporally dissociated, where correlations were made between blood measured at 28 weeks and placentae measured at 38-40 weeks of gestation, suggesting that inverted T cell ratios persisted throughout pregnancy.

Maternal viral load prior to ART initiation correlates with placental, but not cord blood, CD4+ and CD8+ T cell proportions

Maternal viraemia dropped over time from enrolment to delivery (-12 weeks beforehand), where PWH receiving DTG decreased at a faster rate (Figure 2A)[18]. As expected, the enrolment plasma viraemia, ranging from 1.69 - 6.0 log₁₀ RNA

copies/ml, significantly inversely correlated with the absolute maternal peripheral blood CD4+ T cell count determined pre-ART, at enrolment (Figure 2B). Pre-ART viremia also showed a significant negative correlation with proportions of CD4+ T cells in the decidua parietalis and basalis (Figure 2C) and a positive correlation with CD8+ T cells in the decidua parietalis, basalis and villous tissue at delivery (Figure 2D). The association between maternal viral load over time and the proportions of decidual CD4+ and CD8+ T cells were maintained at -8 weeks and -4 weeks before delivery for CD4+ T cells (Supplementary Figure 7) and up to -8 weeks before delivery for CD8+ T cells (Supplementary Figure 8). Maternal viremia did not correlate with the proportion of T cells in the cord blood (Figure 2C and 2D), suggesting that maternal viremia (pre- and post-ART initiation) can influence the homeostatic balance of T cells in the placenta, but not in the “newborn” immune compartment.

Immunohistochemistry confirms anatomical location and fetal origin of CD8+ T cells in villous tissue

Analysis of placental villi from 13 PWH and 3 PWNH controls showed the presence of CD8+ cells in the fetal capillaries (Figure 3A). The numbers of CD8+ T cells positively correlated with pre-ART maternal viremia (Figure 3B), confirming the flow cytometric analysis (Figures 1A, 2D). Using FISH to detect X and Y chromosomes in cells located within the villi from 5 placentae with male births, we confirmed the presence of male (fetal) cells in fetal capillaries (Figure 3C). Thus, the immunohistochemistry analysis confirms the anatomical location and fetal origin of the increased proportions of CD8+ T cells in villous tissue. The fetal (male) origin of

the CD8+ T cells in placental villi is consistent with the absence of villitis of unknown etiology (VUE), a lesion that is characterized by maternal immune infiltrates[23,24].

HIV exposure increases differentiation of CD8+ T cells in placental villi and fetal cord blood, but not in the maternal placental compartments

CD45RA and CD28 were used to identify the proportions of naïve (CD45RA+CD28+), early differentiated (ED, CD45RA-CD28+), late differentiated (LD, CD45RA-CD28-) and terminally differentiated (TD, CD45RA+CD28-) memory CD4+ and CD8+ T cells from villous tissue and matching cord blood (Figure 4A). We observed significantly lower proportions of naïve CD8+ T cells and significantly higher proportions of LD CD8+ T cells in villous tissue and cord blood of HEU compared to HUU (Figure 4B). The CD4+ T cells in the villous tissue were predominantly of a naïve and ED phenotype while the cord blood cells were predominantly naïve. There were no significant differences in CD4+ T cell differentiation state based on HIV-exposure (Supplementary Figure 9). In addition, no significant differences in the stage of CD4+ and CD8+ T cell differentiation in the decidua was observed between the HIV groups (Supplementary Figure 10). Thus, the increased differentiation state of CD8+ T cells is confined to the fetal placental and cord blood compartments and not observed in the maternal placental compartments. There was no correlation between maternal pre-ART viremia and memory stage of CD8+ T cells in placental villous tissue and cord blood (data not shown). We additionally showed that there was no association between villous tissue CD8+ T cell memory differentiation and reported adverse events in the infant during the first 12 weeks of life (Supplementary Figure 11).

Discussion

We present data from a unique cohort of PWH who initiated ART late in pregnancy and show that maternal HIV infection has a clear impact on T cell subsets in the decidua, villous tissue and cord blood. As the decidua and decidual immune cells are of maternal origin, it may not be surprising to find such a footprint[25]. Maternal HIV infection likely affects and kills maternal decidual CD4+ T cells and fewer peripheral blood T cells may traffic to decidual tissue; chemokine gradients have been shown to play a key role in the trafficking of maternal T cells into the decidua during pregnancy[26]. We show that in contrast to the decidua, the inverted CD4:CD8 ratio in the villous tissue was largely due to an increased proportion of CD8+ T cells and not, as observed in the other tissues, due to a decrease in CD4+ T cells. These CD8+ T cells were of an early-late differentiated phenotype, suggestive of previous antigen experience[27,28].

The human placenta has two circulatory compartments: the utero-placental unit for the trafficking of maternal blood and the feto-placental unit for the fetal blood circulation[29,30]. Therefore, cells in the villous tissue are likely to be predominantly from the placental reservoir. A key question is whether the increased CD8+ T cell differentiation in villi and cord blood is due to direct exposure to HIV antigens, presence of other pathogens (e.g. CMV) or increased levels of other non-infectious inflammatory cues in placentae of PWH. Viral particles, structural and core HIV proteins have been shown to cross the placental barrier in the absence of fetal infection leading to altered immune profiles in HEU infants[31,32]. A number of studies also describe HIV-specific T cell responses in HEU infants, possibly primed by exposure to HIV antigens *in utero* [16,33,34].

336

337 The lower proportion of naïve cells and increased memory T cells reflected in villous
338 tissue and cord blood mirror previous studies; HEU infants have been shown to have
339 reduced CD4+ T cell numbers and increased CD8+ T cells compared to HUU infants
340 at birth[35,36]. HEU infants have also been shown to have lower naïve cells thought
341 to be due to thymic involution and frequent stimulation and expansion of the antigen-
342 specific T cells in an effort to regenerate the T cell pool[14,15]. Whether the same
343 findings would be recapitulated in PWH with preconception suppressed viral loads is
344 unknown. Nevertheless, this study afforded us a unique opportunity to investigate
345 the impact of starting ART late in pregnancy and how this affected placental
346 immunity. Being able to compare this with women who are consistently on ART
347 throughout pregnancy would reveal whether long-term viral suppression creates a
348 more normalized immune balance in the placenta.

349

350 It was not possible to tease out the impact between HIV and ART on the
351 placenta/fetus. There is evidence that some ART can cross the placenta [37,38].
352 Additional studies show that perinatal drug exposure associates with lower T cell
353 counts in the first two years in HEU infants[39]. Although we cannot discount the
354 effect of ART alone on the placenta, the parent study did report on minimal effects of
355 ART on the newborn child[18]. A limitation of our study was only having maternal
356 CD4 and CD8 T cell counts at week 28 gestation in PWH and no equivalent
357 measures in PWNH. We therefore could not directly compare the impact of HIV/ART
358 exposure on systemic T cells compared to placental T cells at delivery and nor in
359 healthy mothers.

360

The elevated proportions of CD8+ T cells found embedded in the villi from PWH were shown to be sequestered within the fetal capillaries. These CD8+ T cells within villi were proportional to maternal viremia. The absence of overt VUE corroborates the finding that expanded CD8+ T cell fractions are of fetal and not maternal origin. Previous studies have suggested that the presence of T cells in the villi during normal pregnancy reflect VUE[24]. However, there is emerging evidence, using IHC staining of villi sections from early elective termination placentae, of the presence of CD45+ $\alpha\beta$ T cells, although these cells were undetectable at term[40]. In a separate study, where there were no reported maternal infections, the villous tissue was shown to contain a mixture of fetal and maternal immune cells[41]. We cannot discount the possibility that there was also a mix of maternal and fetal CD8+ T cells in placental villi in our study.

Here, we demonstrate that within the feto-placental unit, there are differences between the T cell profiles in the villi and cord blood. We postulate that the cells we characterized in the villi may be a combination of cells within the villi, and cells attached to the fetal capillaries. Contaminating circulating cord blood cells in this fraction cannot be completely ruled out but is minimized by extensive washing of the tissues prior to isolation. Moreover, the phenotypic differences between villous and cord blood T cells as presented here suggest that the villous T cells do not include large proportions of circulating T cells. The increased differentiation state of CD8+ T cells in the villi may be due to exposure to antigens within the villous microenvironment as well as the mechanisms of immune activation leading to T cells adhesion and extravasation. Attempts to make a direct connection between the elevated numbers and proportions of CD8+ T cells found in the villous tissue with

adverse health events in the first few weeks after birth, revealed no association;
most events were resolving rashes.

Of particular note, women were ART naïve during the first and second trimester and it is likely that prolonged HIV exposure may have contributed to altered placental development and the significantly lower placental weight observed. Interestingly, all cases of maternal vascular malperfusion (MVM) were reported in placentae from PWH and possibly reflects placental injury affecting maternal vasculature and perfusion and increasing the risk of an adverse birth outcome[42]. We have previously reported on MVM in placentae from PWH on long-term ART, an incidence of about 27% overall, similar to Kalk *et al* [6,21]. It is likely that HIV and/or ART exposure alters factors involved in vascular development, resulting in placental insufficiency and increased risk of adverse birth outcomes[8,9,43].

In conclusion, we provide evidence that *in utero* exposure to HIV results in an altered immune balance in both the utero-placental and feto-placental compartments. Despite the initiation of ART in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Overall, our results suggest that maternal immunity leaves a footprint in the placenta that may shape the neonatal/infant immune landscape.

409 **Author contributions**

410 NMI, ML, SK, LM, HBJ, CMG: Conceptualization and design of the study

411 NMI, TT: Panel design, sample preparation and development of methods

412 KP: Histopathology scoring and interpretation

413 NMI, TRM and SD: Statistical analysis

414 NMI, TT, KP, TM, LM, EAE, RC, HBJ, CMG: Writing the manuscript

415

416 **Acknowledgments**

417 We wish to thank all the study participants in this study; all the members of the

418 DOLPHIN-2 clinical trial and INFANT placenta study. We also wish to thank

419 Nonzwakazi Bangani, Goitseone Thamae, Michelle Barboure, Berenice Alinde and

420 Lizette Fick for their expert assistance in sample processing and Dr Amsha

421 Ramburan for capturing the FISH images.

422

423

424 **Footnotes**

425 **Conflict of interest statement**

426 The authors have declared that no conflict of interest exists.

427

428 **Funding**

429 This research was supported by a Fellowship to NMI from the AXA Research Fund,
430 Paris and partly through R01HD102050-01. The content is solely the responsibility of
431 the authors and does not necessarily represent the official views of those of the AXA
432 Research Fund. The research is part of the DOLPHIN-2 clinical trial sponsored by
433 UNITAID (ClinicalTrials.gov NCT03249181).

434

435 **Corresponding Author**

436 Clive M Gray, Division of Immunology, Institute of Infectious Disease and Molecular
437 Medicine, Falmouth Building, Faculty of Health Sciences, University of Cape Town,
438 Anzio Road, Observatory, Cape Town, South Africa, 7925; Tel: +27 21 406 6616;
439 Email: clive.gray@uct.ac.za

440

441

442

Figure Legends

Figure 1: Proportions of T cells in the placenta and cord blood

(A) Box plots (showing medians and interquartile ranges) of CD3+CD4+CD8- T cells and CD3+CD4-CD8+ T cell proportions isolated from the decidua parietalis, decidua basalis, villous tissue and cord blood from Pregnant Women not living with HIV (PWNH) and Pregnant Women with HIV (PWH) and HIV unexposed uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. **(B)** Box plots (showing medians and interquartile ranges) of CD4:CD8 T cell ratios in the decidua parietalis, decidua basalis, villous tissue and cord blood from Pregnant Women not living with HIV (PWNH) and Pregnant Women with HIV (PWH) and HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. Tests of significance were performed using the Mann-Whitney *U* test. **(C)** Correlation plots between the absolute maternal CD4 count at 28 weeks' gestation prior to ART initiation and the proportion of CD4+ T cells isolated from the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded areas represent the 95% confidence intervals. **(D)** Correlation plots between the absolute maternal CD4 count at 28 weeks' gestation prior to ART initiation and the proportion of CD8+ T cells isolated from the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded areas represent the 95% confidence intervals.

Figure 2: Proportions of CD4+ and CD8+ T cells in the placenta and maternal viral load

(A) Line plot depicting participant viral load trajectories over time at ART initiation which was at 28 weeks' gestation (VLV1, 12 weeks before delivery), 29 weeks' gestation (VLV2, 8 weeks before delivery), 33 weeks' gestation (VLV3, 4 weeks before delivery), 36 weeks' gestation (VLV4, 2 weeks before delivery) and at day 14 after delivery (VLV5, +/- 2 weeks after delivery). The women received efavirenz (EFV + TDF + 3TC) (denoted in black) and dolutegravir (DTG + TDF + 3TC) (denoted in blue). **(B)** Correlation plot between maternal systemic absolute CD4 counts at enrolment prior to ART initiation with maternal viral load at enrolment and ART initiation (28 weeks GA). Statistical analysis was performed using the Spearman rank test and the grey shaded area represents the 95% confidence intervals. **(C)** Correlation plots between CD4+ T cell proportions in the placenta and maternal viral load at enrolment and ART initiation (28 weeks GA) in the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded area represents the 95% confidence intervals. **(D)** Correlation plots between CD8+ T cell proportions in the placenta and maternal viral load at enrolment and ART initiation (28 weeks GA) in the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded area represents the 95% confidence intervals.

Figure 3: Anatomical location of CD8+ T cells in the villous tissue

(A) Representative immunohistochemical stained images of CD8+ T cells in villous tissue sections denoted in brown dots and black arrows in the villi of placentae from HIV-infected and -uninfected mothers (40x magnification). **(B)** Correlation plot between the density of tissue-bound CD8+ T cells in the villi and maternal viral load at ART initiation (pre-ART). Statistical analysis was performed using the Spearman

rank test and the black curved lines represent the 95% confidence intervals. **(C)** Representative Fluorescence in situ Hybridization (FISH) images of lymphocytes (white arrows) in the villous tissue from placentas from male infants. The X chromosome is denoted in green and Y chromosome denoted in red (digitally scanned slides).

Figure 4: Memory phenotype of CD4 and CD8 T cells in the Villous Tissue

(A) Representative flow cytometry contour plots of Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) CD4+ T cells and CD8+ T cells in the villous tissue (VT; upper panel) of placentae from PWNH and PWH and cord blood from HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU). **(B)** Box plots (showing medians and interquartile ranges) of CD8+ Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) T cells in the villous tissue and cord blood from HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU). Tests of significance were performed using the Mann-Whitney *U* test.

Supplementary Figures

Supplementary Figure 1: Lymphocyte isolation from the human placenta

Stepwise isolation of lymphocytes from the human placenta decidua parietalis (DP), decidua basalis (DB) and villous tissue (VT): (1) dissection of the whole placenta; (2) multiple rounds of maternal blood rinsing to avoid contamination followed by enzymatic digestion of each dissected tissue; (3) lymphocyte separation obtained by Percoll density centrifugation; (4) cryopreservation of fixed cells and immunophenotyping using flow cytometry. Image created with Biorender.com.

517

518 **Supplementary Figure 2: Gating strategy to delineate CD3+ T cells**

519 Representative flow cytometry dot plots depicting the gating strategy to delineate
520 CD4+ and CD8+ T cells gated from a live CD45+ CD14- CD3+ population in the
521 placenta.

522

523 **Supplementary Figure 3: Proportions of T cells in the placenta and cord blood**
524 **by ART group**

525 **(A)** Box plots (showing medians and interquartile ranges) of CD3+CD4+CD8- T cells
526 and CD3+CD4-CD8+ T cell proportions isolated from the decidua parietalis, decidua
527 basalis, villous tissue and cord blood from Pregnant Women not living with HIV
528 (PWNH) and Pregnant Women with HIV (PWH) and HIV unexposed uninfected
529 (HUU) and HIV exposed uninfected (HEU) cord bloods. **(B)** Box plots (showing
530 medians and interquartile ranges) of CD4:CD8 T cell ratios in the decidua parietalis,
531 decidua basalis, villous tissue and cord blood from Pregnant Women not living with
532 HIV (PWNH) and Pregnant Women with HIV (PWH) and HIV unexposed and
533 uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. Tests of
534 significance were performed using the Mann-Whitney *U* test.

535

536 **Supplementary Figure 4: Proportions of T cells in the placenta and cord blood**
537 **stratified by placental weight**

538 (A) Histogram (showing medians and interquartile ranges) of CD3+CD4+CD8- T
539 cells, (B) CD3+CD4-CD8+ T cells proportions and (C) CD4:CD8 T cell ratios
540 stratified by placental weight in placentas from Pregnant Women not living with HIV
541 (PWNH) and Pregnant Women with HIV (PWH). Tests of significance were

performed using the Kruskal-Wallis test.

Supplementary Figure 5: Proportions of T cells in the placenta and cord blood stratified by gravidity

(A) Histogram (showing medians and interquartile ranges) of CD3+CD4+CD8- T cells, (B) CD3+CD4-CD8+ T cells proportions and (C) CD4:CD8 T cell ratios stratified by gravidity in placentas from Pregnant Women not living with HIV (PWNH) and Pregnant Women with HIV (PWH). Tests of significance were performed using the Kruskal-Wallis test.

Supplementary Figure 6: Proportions of T cells in the placenta and cord blood stratified by gestational age at delivery

(A) Histogram (showing medians and interquartile ranges) of CD3+CD4+CD8- T cells, (B) CD3+CD4-CD8+ T cells proportions and (C) CD4:CD8 T cell ratios stratified by gestational age at delivery in placentas from Pregnant Women not living with HIV (PWNH) and Pregnant Women with HIV (PWH). Tests of significance were performed using the Kruskal-Wallis test.

Supplementary Figure 7: Proportions of CD4+ T cells in the placenta, cord blood and maternal viral load

Correlation plots between CD4+ T cell proportions in the placenta and cord blood and maternal viral load at 29 weeks' gestation (VLV2, 8 weeks before delivery), 33 weeks' gestation (VLV3, 4 weeks before delivery) and 36 weeks' gestation (VLV4, 2 weeks before delivery) in the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey

shaded area represents the 95% confidence intervals.

Supplementary Figure 8: Proportions of CD8+ T cells in the placenta, cord blood and maternal viral load

Correlation plots between CD8+ T cell proportions in the placenta and cord blood and maternal viral load at 29 weeks' gestation (VLV2, 8 weeks before delivery), 33 weeks' gestation (VLV3, 4 weeks before delivery) and 36 weeks' gestation (VLV4, 2 weeks before delivery) in the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded area represents the 95% confidence intervals.

Supplementary Figure 9: Memory differentiation of CD4+ T cells in the villous tissue and cord blood

Box plots (showing medians and interquartile ranges) of CD4+ Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) T cells in the villous tissue (VT; upper panel) and cord blood (CB; lower panel) from HIV-uninfected (MHIV neg) and infected mothers (MHIV pos) and HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. Tests of significance were performed using the Mann-Whitney *U* test.

Supplementary Figure 10: Memory differentiation of CD4 and CD8 T cells in the decidua parietalis and decidua basalis

(A) Representative flow cytometry contour plots of Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) CD4+ T cells and CD8+ T cells in the decidua parietalis and basalis of placentae from PWNH and PWH. **(B)**

592 Box plots (showing medians and interquartile ranges) of CD4+ and **(C)** CD8+ Naïve,
 593 Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) T
 594 cells in the decidua parietalis and basalis of placentae from PWNH and PWH.

595

596 **Supplementary Figure 11: Proportion of CD8+ T cells in the Villous Tissue and**
 597 **Adverse Events in HEU in the first three months of life.**

598 Scatter plot showing the proportion of CD8+ T cells delineated by naïve, early
 599 differentiated memory, late differentiated and terminally differentiated memory in
 600 HEU infants comparing adverse events with no events reported.

601

602

References

1. Okoye AA, Picker LJ. CD4 + T-cell depletion in HIV infection: mechanisms of immunological failure. *Immunol Rev* [Internet]. 2013 Jul;254(1):54–64. Available from: <http://doi.wiley.com/10.1111/imr.12066>
2. Demers KR, Makedonas G, Buggert M, et al. Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. Douek DC, editor. *PLOS Pathog* [Internet]. 2016 Aug 3;12(8):e1005805. Available from: <http://dx.plos.org/10.1371/journal.ppat.1005805>
3. Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV. *Curr HIV/AIDS Rep* [Internet]. 2017;14(3):93–100. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28434169>
4. Okhai H, Vivancos-Gallego MJ, Hill T, Sabin CA. CD4+:CD8+ T Cell Ratio Normalization and the Development of AIDS Events in People with HIV Starting Antiretroviral Therapy. *AIDS Res Hum Retroviruses* [Internet]. 2020 Oct 1;36(10):808–16. Available from: <https://www.liebertpub.com/doi/10.1089/aid.2020.0106>
5. Uthman OA, Nachega JB, Anderson J, et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. *Lancet HIV* [Internet]. 2017 Jan;4(1):e21–30. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2352301816301953>
6. Kalk E, Schubert P, Bettinger JA, et al. Placental pathology in HIV infection at term: a comparison with HIV-uninfected women. *Trop Med Int Health* [Internet]. 2017;22(5):604–13. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28214384>
7. Mwanyumba F, Gaillard P, Inion I, et al. Placental Inflammation and Perinatal

- 628 Transmission of HIV-1. JAIDS J Acquir Immune Defic Syndr [Internet]. 2002
629 Mar;29(3):262–9. Available from: [http://journals.lww.com/00126334-](http://journals.lww.com/00126334-200203010-00006)
630 200203010-00006
- 631 8. Mohammadi H, Papp E, Cahill L, et al. HIV antiretroviral exposure in
632 pregnancy induces detrimental placenta vascular changes that are rescued by
633 progesterone supplementation. Sci Rep [Internet]. 2018 Dec 26;8(1):6552.
634 Available from: <http://www.nature.com/articles/s41598-018-24680-w>
- 635 9. Kala S, Dunk C, Acosta S, Serghides L. Periconceptional exposure to
636 lopinavir, but not darunavir, impairs decidualization: a potential mechanism
637 leading to poor birth outcomes in HIV-positive pregnancies. Hum Reprod
638 [Internet]. 2020 Aug 1;35(8):1781–96. Available from:
639 <https://academic.oup.com/humrep/article/35/8/1781/5876549>
- 640 10. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation
641 abnormalities in uninfected newborns and children with vertical exposure to
642 HIV. Blood [Internet]. 2000 Dec 1;96(12):3866–71. Available from:
643 <http://www.ncbi.nlm.nih.gov/pubmed/11090071>
- 644 11. Abu-Raya B, Kollmann TR, Marchant A, MacGillivray DM. The Immune
645 System of HIV-Exposed Uninfected Infants. Front Immunol [Internet].
646 2016;7:383. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27733852>
- 647 12. Kakkar F, Lamarre V, Ducruet T, et al. Impact of maternal HIV-1 viremia on
648 lymphocyte subsets among HIV-exposed uninfected infants: protective
649 mechanism or immunodeficiency. BMC Infect Dis [Internet]. 2014 May
650 5;14:236. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24885498>
- 651 13. Ono E, Santos AMN dos, Succi RC de M, et al. Imbalance of naive and
652 memory T lymphocytes with sustained high cellular activation during the first

- 653 year of life from uninfected children born to HIV-1-infected mothers on HAART.
654 Brazilian J Med Biol Res [Internet]. 2008 Aug;41(8):700–8. Available from:
655 [http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000800011&lng=en&tlng=en)
656 [879X2008000800011&lng=en&tlng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000800011&lng=en&tlng=en)
- 657 14. Mansoor N, Abel B, Scriba TJ, et al. Significantly skewed memory CD8+ T cell
658 subsets in HIV-1 infected infants during the first year of life. Clin Immunol
659 [Internet]. 2009 Mar;130(3):280–9. Available from:
660 <http://www.ncbi.nlm.nih.gov/pubmed/18996749>
- 661 15. Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence during
662 aging. Curr Opin Immunol [Internet]. 2005 Oct;17(5):480–5. Available from:
663 <http://www.ncbi.nlm.nih.gov/pubmed/16098721>
- 664 16. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-
665 Jones SL. HIV-exposed uninfected children: a growing population with a
666 vulnerable immune system? Clin Exp Immunol [Internet]. 2014 Apr;176(1):11–
667 22. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24325737>
- 668 17. Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the
669 global population of children who are HIV-exposed and uninfected, 2000–18: a
670 modelling study. Lancet Glob Heal [Internet]. 2020 Jan;8(1):e67–75. Available
671 from: <https://linkinghub.elsevier.com/retrieve/pii/S2214109X19304486>
- 672 18. Kintu K, Malaba TR, Nakibuka J, et al. Dolutegravir versus efavirenz in women
673 starting HIV therapy in late pregnancy (DoIPHIN-2): an open-label, randomised
674 controlled trial. Lancet HIV [Internet]. 2020 May;7(5):e332–9. Available from:
675 <https://linkinghub.elsevier.com/retrieve/pii/S2352301820300503>
- 676 19. Tilburgs T, Crespo ÂC, van der Zwan A, et al. Human HLA-G+ extravillous
677 trophoblasts: Immune-activating cells that interact with decidual leukocytes.

- 678 Proc Natl Acad Sci [Internet]. 2015 Jun 9;112(23):7219–24. Available from:
679 <http://www.pnas.org/lookup/doi/10.1073/pnas.1507977112>
- 680 20. Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental
681 Lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch
682 Pathol Lab Med [Internet]. 2016 Jul;140(7):698–713. Available from:
683 <http://www.archivesofpathology.org/doi/10.5858/arpa.2015-0225-CC>
- 684 21. Ikumi NM, Malaba TR, Pillay K, et al. Differential impact of antiretroviral
685 therapy initiated before or during pregnancy on placenta pathology in HIV-
686 positive women. AIDS [Internet]. 2021 Feb 3; Publish Ah. Available from:
687 <https://journals.lww.com/10.1097/QAD.0000000000002824>
- 688 22. R Core Team. R: A language and environment for statistical computing
689 [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020.
690 Available from: <https://www.r-project.org/>
- 691 23. Enninga EAL, Raber P, Quinton RA, et al. Maternal T Cells in the Human
692 Placental Villi Support an Allograft Response during Noninfectious Villitis. J
693 Immunol [Internet]. 2020 Jun 1;204(11):2931–9. Available from:
694 <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1901297>
- 695 24. Tamblyn JA, Lissauer DM, Powell R, Cox P, Kilby MD. The immunological
696 basis of villitis of unknown etiology – Review. Placenta [Internet]. 2013
697 Oct;34(10):846–55. Available from:
698 <https://linkinghub.elsevier.com/retrieve/pii/S0143400413005894>
- 699 25. Ander SE, Diamond MS, Coyne CB. Immune responses at the maternal-fetal
700 interface. Sci Immunol [Internet]. 2019 Jan 11;4(31):eaat6114. Available from:
701 <http://immunology.sciencemag.org/lookup/doi/10.1126/sciimmunol.aat6114>
- 702 26. Huang Y, Zhu X-Y, Du M-R, Li D-J. Human trophoblasts recruited T

- 703 lymphocytes and monocytes into decidua by secretion of chemokine CXCL16
- 704 and interaction with CXCR6 in the first-trimester pregnancy. J Immunol
- 705 [Internet]. 2008 Feb 15;180(4):2367–75. Available from:
- 706 <http://www.ncbi.nlm.nih.gov/pubmed/18250446>
- 707 27. Tilburgs T, Strominger JL. CD8+ Effector T Cells at the Fetal-Maternal
- 708 Interface, Balancing Fetal Tolerance and Antiviral Immunity. Am J Reprod
- 709 Immunol [Internet]. 2013 Apr;69(4):395–407. Available from:
- 710 <http://doi.wiley.com/10.1111/aji.12094>
- 711 28. White JT, Cross EW, Kedl RM. Antigen-inexperienced memory CD8+ T cells:
- 712 where they come from and why we need them. Nat Rev Immunol [Internet].
- 713 2017 Jun;17(6):391–400. Available from:
- 714 <http://www.ncbi.nlm.nih.gov/pubmed/28480897>
- 715 29. Dawe GS, Tan XW, Xiao Z-C. Cell migration from baby to mother. Cell Adh
- 716 Migr [Internet]. 2007;1(1):19–27. Available from:
- 717 <http://www.ncbi.nlm.nih.gov/pubmed/19262088>
- 718 30. Acharya G, Sonesson S-E, Flo K, Räsänen J, Odibo A. Hemodynamic aspects
- 719 of normal human fetoplacental (umbilical) circulation. Acta Obstet Gynecol
- 720 Scand [Internet]. 2016 Jun;95(6):672–82. Available from:
- 721 <http://doi.wiley.com/10.1111/aogs.12919>
- 722 31. Nielsen SD, Jeppesen DL, Kolte L, et al. Impaired progenitor cell function in
- 723 HIV-negative infants of HIV-positive mothers results in decreased thymic
- 724 output and low CD4 counts. Blood [Internet]. 2001 Jul 15;98(2):398–404.
- 725 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11435309>
- 726 32. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new
- 727 global challenges in the era of paediatric HIV elimination. Lancet Infect Dis

- 728 [Internet]. 2016 Jun;16(6):e92–107. Available from:
729 <https://linkinghub.elsevier.com/retrieve/pii/S1473309916000554>
- 730 33. Kuhn L, Coutoudis A, Moodley D, et al. T-helper cell responses to HIV
731 envelope peptides in cord blood: protection against intrapartum and breast-
732 feeding transmission. AIDS [Internet]. 2001 Jan 5;15(1):1–9. Available from:
733 <http://www.ncbi.nlm.nih.gov/pubmed/11192849>
- 734 34. Holditch SJ, Eriksson EM, Tarosso LF, et al. Decay kinetics of HIV-1 specific T
735 cell responses in vertically HIV-1 exposed seronegative infants. Front Immunol
736 [Internet]. 2011;2:94. Available from:
737 <http://www.ncbi.nlm.nih.gov/pubmed/22566883>
- 738 35. Huo Y, Patel K, Scott GB, et al. Lymphocyte subsets in HIV-exposed
739 uninfected infants and HIV-unexposed uninfected infants. J Allergy Clin
740 Immunol [Internet]. 2017 Aug;140(2):605-608.e3. Available from:
741 <https://linkinghub.elsevier.com/retrieve/pii/S009167491730338X>
- 742 36. Borges-Almeida E, Milanez HM, Vilela MMS, et al. The impact of maternal HIV
743 infection on cord blood lymphocyte subsets and cytokine profile in exposed
744 non-infected newborns. BMC Infect Dis [Internet]. 2011 Dec 3;11(1):38.
745 Available from: [http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-](http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-11-38)
746 [2334-11-38](http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-11-38)
- 747 37. Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of
748 dolutegravir in pregnant mothers with HIV infection and their neonates: A
749 randomised trial (DOLPHIN-1 study). Mofenson LM, editor. PLOS Med
750 [Internet]. 2019 Sep 20;16(9):e1002895. Available from:
751 <https://dx.plos.org/10.1371/journal.pmed.1002895>
- 752 38. Kreitchmann R, Schalkwijk S, Best B, et al. Efavirenz pharmacokinetics during

- 753 pregnancy and infant washout. Antivir Ther [Internet]. 2018;24(2):95–103.
754 Available from:
755 <https://www.intmedpress.com/journals/avt/abstract.cfm?id=3283&pid=48>
- 756 39. Pacheco SE, McIntosh K, Lu M, et al. Effect of Perinatal Antiretroviral Drug
757 Exposure on Hematologic Values in HIV-Uninfected Children: An Analysis of
758 the Women and Infants Transmission Study. J Infect Dis [Internet]. 2006 Oct
759 15;194(8):1089–97. Available from: [https://academic.oup.com/jid/article-](https://academic.oup.com/jid/article-lookup/doi/10.1086/507645)
760 [lookup/doi/10.1086/507645](https://academic.oup.com/jid/article-lookup/doi/10.1086/507645)
- 761 40. Bonney EA, Pudney J, Anderson DJ, Hill JA. Gamma-Delta T Cells in
762 Midgestation Human Placental Villi. Gynecol Obstet Invest [Internet].
763 2000;50(3):153–7. Available from:
764 <https://www.karger.com/Article/FullText/10315>
- 765 41. Pique-Regi R, Romero R, Tarca AL, et al. Single cell transcriptional signatures
766 of the human placenta in term and preterm parturition. Elife [Internet]. 2019
767 Dec 12;8. Available from: <https://elifesciences.org/articles/52004>
- 768 42. Ernst LM. Maternal vascular malperfusion of the placental bed. APMIS
769 [Internet]. 2018 Jul;126(7):551–60. Available from:
770 <http://doi.wiley.com/10.1111/apm.12833>
- 771 43. Weckman AM, Ngai M, Wright J, McDonald CR, Kain KC. The Impact of
772 Infection in Pregnancy on Placental Vascular Development and Adverse Birth
773 Outcomes. Front Microbiol [Internet]. 2019 Aug 22;10. Available from:
774 <https://www.frontiersin.org/article/10.3389/fmicb.2019.01924/full>
775
776

777 **Table 1: Maternal and infant characteristics**

	HIV-Uninfected N=9	HIV-Infected N=21	P-Value
Age, years			1.0
≤24	1 (11.1)	2 (9.5)	
25-29	5 (55.6)	11 (52.4)	
≥30	3 (33.3)	8 (38.1)	
Median (IQR)	29 (25 - 31)	29 (26 - 30)	
Median gestation at enrolment	30 (26 - 32)	28 (28 - 31)	0.6
Gravidity			0.003
1	5 (55.6)	1 (4.8)	
2	3 (33.3)	7 (33.3)	
≥3	1 (11.1)	13 (61.9)	
Median (IQR)	1 (1 - 2)	3 (2 - 3)	
Infant Characteristics			
Sex			1.0
Female	6 (66.7)	12 (57.1)	
Male	3 (33.3)	6 (28.6)	
Missing	0 (0)	3 (14.3)	
Median gestation at delivery (completed weeks)	40 (40)	39 (38 - 39)	0.003
Birthweight in grams, Median (IQR)	3420 (3420 - 4000)	3305 (3010 - 3570)	0.07

778

779

Table 2: Placental characteristics and pathology at delivery

	HIV-Uninfected N=9	HIV-Infected N=21	P-Value
Placental basal plate weight (g), median (IQR)	468 (426 - 533)	394 (343 - 469)	0.02
Placental weight (g)			0.03
Small (<10 th percentile)	0 (0)	8 (38.1)	
Appropriate (10 - 90 th percentile)	9 (100.0)	12 (57.1)	
Large (>90 th percentile)	0 (0)	0 (0)	
Missing	0 (0)	1 (4.8)	
Fetal-Placenta weight ratio			0.02
Small (<10 th percentile)	1 (11.1)	0 (0)	
Appropriate (10 - 90 th percentile)	8 (88.9)	11 (52.4)	
Large (>90 th percentile)	0 (0)	7 (33.3)	
Missing	0 (0)	3 (14.9)	
Placenta greatest diameter (mm), median (IQR)	180 (172 - 210)	180 (170 - 199)	0.6
Placenta thickness (mm), median (IQR)	20 (15 -20)	25 (16.5 - 27.5)	0.2
Cord insertion			0.7
Central	3 (33.3)	3 (33.3)	
Off centre	5 (55.6)	12 (57.1)	
Marginal	1 (11.1)	5 (23.8)	
Missing	0 (0)	1 (4.76)	
Meconium exposure			0.1
+	3 (33.3)	2 (9.5)	
-	6 (66.7)	19 (90.5)	
Chorioamnionitis			
Maternal Inflammatory Response			0.6
+	2 (22.2)	2 (9.5)	
-	7 (77.8)	19 (90.5)	
Fetal Inflammatory Response			0.6
+	2 (22.2)	3 (14.3)	
-	7 (77.8)	18 (85.7)	
Chronic Deciduitis			0.5
+	0 (0)	2 (9.5)	
-	9 (100)	19 (90.5)	
Maternal Vascular Malperfusion			0.09
+	0 (0)	6 (28.6)	
-	9 (100)	15 (71.4)	
Villitis of Unknown Etiology			1.0
+	0 (0)	0 (0)	
-	9 (100)	21 (100)	

781

782

783

Figure 1

A CD3+CD4+CD8- T cells

CD3+CD4-CD8+ T cells

B CD4:CD8 T cell ratio

Figure 1

Figure 2

Figure 2

Figure 3

medRxiv preprint doi: <https://doi.org/10.1101/2021.01.04.21249198>; this version posted April 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Figure 4